Organogenesis vs Xeris Biopharma
ORGO and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ORGO and XERS compare
Xeris Biopharma is the larger company, worth 29 times as much as Organogenesis ($3.0B against $103M).
Xeris Biopharma grew revenue faster over the last twelve months (36.3% versus 6.5% for Organogenesis).
Xeris Biopharma keeps more of each dollar of sales as profit, with a net margin of −5.1% compared with −18.4% at Organogenesis.
Xeris Biopharma scores higher on the StockData Score (10 against 9 for Organogenesis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ORGO | XERS |
|---|---|---|
| Size and price | ||
| Market cap | $103M | $3.0B |
| Share price | $0.803 | $16.70 |
| Change, 1 year | −87.1% | 130% |
| Change, 5 years | −91.9% | 670% |
| Beta (5Y) | 0.59 | 0.28 |
| Employees | 854 | 435 |
| StockData Score | ||
| Total score | 9 | 10 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 4 (better) |
| Performance score | 3 | 3 |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.2× (better) | 9.1× |
| P/B | 0.7× | – |
| EV/EBITDA | – | 83.7× |
| P/FCF | 5.0× | – |
| FCF yield | 20.2% | – |
| Growth | ||
| Revenue growth (TTM) | 6.5% | 36.3% (better) |
| Revenue growth, 5Y average | 10.8% | 70.2% (better) |
| EPS growth, 5Y average | 0.00% | – |
| Profitability | ||
| Gross margin | – | 86.6% |
| Operating margin | −7.8% | 10.9% (better) |
| Net margin | −18.4% | −5.1% (better) |
| FCF margin | 4.6% | – |
| Return on equity | −44.1% | – |
| Return on invested capital | −21.7% | 22.1% (better) |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Net debt / EBITDA | – | 3.45 |
| Interest coverage | – | 1.3× |
| Current ratio | 3.52 (better) | 1.45 |
| Altman Z-score | 1.26 | 3.31 (better) |
| Piotroski F-score | 5 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 53.2% | 59.4% |
| Held by insiders | – | 5.2% |
| Insider net buying, 12 months | −$988K (better) | −$5.8M |
| Short interest, % of float | – | 5.2% |
Go deeper
- ORGO stock overview
- ORGO income statement
- ORGO valuation and score
- XERS stock overview
- XERS income statement
- XERS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.